排序方式: 共有7条查询结果,搜索用时 6 毫秒
1
1.
2.
Roberto M. Lang MD FASE Michelle Bierig MPH RDCS FASE Richard B. Devereux MD Frank A. Flachskampf MD Elyse Foster MD Patricia A. Pellikka MD Michael H. Picard MD Mary J. Roman MD James Seward MD Jack S. Shanewise MD FASE Scott D. Solomon MD Kirk T. Spencer MD FASE Martin St John Sutton MD FASE William J. Stewart MD Members of the Chamber Quantification Writing Group 《Journal of the American Society of Echocardiography》2005,18(12):119-1463
3.
Losartan 在健康人体中药效学和药代学的研究 总被引:1,自引:0,他引:1
目的:探讨Losartan在体内对肾素-血管紧张素系统的影响以及国人体内losartan代谢过程,为解释其降压机理及临床合理用药提供参考;方法:以健康受试者为研究对象,采用随机、双盲给予药物和安慰剂,观察受试者血压和体内肾素的变化,以及losartan及其代谢产物在体内代谢过程。结果:血压在用药后6h内下降幅度较大,而肾素活性在8h左右升高幅度最大。以及losartan在服药后3h,药物浓度达到高峰,而其代谢产物EXP3174在服药后8h血药浓度达高峰。血浆肾素活性和EXP3174的AUC0-24成正相关。结论:losartan的降低血压与其代谢产物EXP3174作用直接相关,在降压幅度最大时,肾素的活性也达到最高点。这可能与血管紧张素系统的自身调节有关。 相似文献
4.
5.
Chamber R.; Miller D.; Tweed P.; Campbell I. 《Occupational medicine (Oxford, England)》1997,47(8):485-490
A research nurse interviewed 55 practice staff in 11 generalpractices to ascertain their views about their needs for occupationalhealth care. In a second parallel study, a specialist in occupationalmedicine undertook an in-depth audit of occupational healthprovision in five other general practices with respect to theorganization, the health and safety process, the services andthe working environment. In the first study, the majority ofpractice staff reported the need for various aspects of occupationalhealth care, particularly stress at work. In the second study,general practitioners and practice managers possessed a basicawareness of occupational health matters such as Health andSafety legislation, but their limited knowledge was not translatedinto effective management. General practice staff did not knowwhere to obtain occupational health advice; most practices hadno policies or procedures in place to manage health and safety.Both studies illustrate the need for expert occupational healthadvice in primary care. 相似文献
6.
7.
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial 总被引:21,自引:0,他引:21
Wilkoff BL Cook JR Epstein AE Greene HL Hallstrom AP Hsia H Kutalek SP Sharma A;Dual Chamber VVI Implantable Defibrillator Trial Investigators 《JAMA》2002,288(24):3115-3123
Context Implantable cardioverter defibrillator (ICD) therapy with backup ventricular pacing increases survival in patients with life-threatening ventricular arrhythmias. Most currently implanted ICD devices provide dual-chamber pacing therapy. The most common comorbid cause for mortality in this population is congestive heart failure. Objective To determine the efficacy of dual-chamber pacing compared with backup ventricular pacing in patients with standard indications for ICD implantation but without indications for antibradycardia pacing. Design The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial, a single-blind, parallel-group, randomized clinical trial. Setting and Participants A total of 506 patients with indications for ICD therapy were enrolled between October 2000 and September 2002 at 37 US centers. All patients had a left ventricular ejection fraction (LVEF) of 40% or less, no indication for antibradycardia pacemaker therapy, and no persistent atrial arrhythmias. Interventions All patients had an ICD with dual-chamber, rate-responsive pacing capability implanted. Patients were randomly assigned to have the ICDs programmed to ventricular backup pacing at 40/min (VVI-40; n = 256) or dual-chamber rate-responsive pacing at 70/min (DDDR-70; n = 250). Maximal tolerated medical therapy for left ventricular dysfunction, including angiotensin-converting enzyme inhibitors and -blockers, was prescribed to all patients. Main Outcome Measure Composite end point of time to death or first hospitalization for congestive heart failure. Results One-year survival free of the composite end point was 83.9% for patients treated with VVI-40 compared with 73.3% for patients treated with DDDR-70 (relative hazard, 1.61; 95% confidence interval [CI], 1.06-2.44). The components of the composite end point, mortality of 6.5% for VVI-40 vs 10.1% for DDDR-70 (relative hazard, 1.61; 95% CI, 0.84-3.09) and hospitalization for congestive heart failure of 13.3% for VVI-40 vs 22.6% for DDDR-70 (relative hazard, 1.54; 95% CI, 0.97-2.46), also trended in favor of VVI-40 programming. Conclusion For patients with standard indications for ICD therapy, no indication for cardiac pacing, and an LVEF of 40% or less, dual-chamber pacing offers no clinical advantage over ventricular backup pacing and may be detrimental by increasing the combined end point of death or hospitalization for heart failure. 相似文献
1